London-based AstraZeneca ranks #9 with a brand value of USD $8.123 billion. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases. It operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
AstraZeneca’s purpose is to push the boundaries of science to deliver life-changing medicines. This commitment is the foundation of their brand positioning ‘What science can do.’
Healthcare professionals (HCPs) acknowledge AstraZeneca’s strong market presence and legacy as a leader in the pharmaceutical sector. The HCPs surveyed were driven to choose AstraZeneca based on the company’s reputation for investing in building strong relationships. HCPs also believe that the company has a high degree of scientific expertise and a strong focus on improving patient outcomes.
In 2014, AstraZeneca reaffirmed its promise of growth by staving off a potential takeover and has since continued to bolster its cardiovascular, metabolic, and respiratory disease franchises through making a series of savvy acquisitions itself.